Capstone Investment Advisors
LGND icon

Capstone Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Capstone Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,153
Closed -$381K – 1865
2025
Q3 		$381K Sell
2,153
-13,219
-86% -$1.97M ﹤0.01% 1538
2025
Q2 		$1.75M Buy
+15,372
New +$1.64M ﹤0.01% 687
2018
Q1 		– Sell
-4,166
Closed -$355K – 464
2017
Q4 		$355K Buy
+4,166
New +$361K 0.01% 335
2016
Q4 		– Sell
-3,544
Closed -$225K – 1030
2016
Q3 		$225K Buy
3,544
+158
+5% +$11.6K ﹤0.01% 662
2016
Q2 		$251K Buy
+3,386
New +$251K ﹤0.01% 589

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Capstone Investment Advisors's LGND Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 2,153 shares — an estimated $381K sold.

Capstone Investment Advisors first reported a position in LGND in Q2 2016 and held it in 5 quarters. The position peaked at $1.75M in Q2 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,153 Ligand Pharmaceuticals shares in Q4 2025, an estimated $381K.
  • Capstone Investment Advisors first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 5 quarters.
  • Capstone Investment Advisors's Ligand Pharmaceuticals position peaked at $1.75M in Q2 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.